Indaptus Therapeutics 3/13/2024 Earnings Report

Indaptus Therapeutics EPS Results

• Actual EPS: -$13.16
• Consensus EPS: -$15.12
• Beat/Miss: Beat by +$1.96
• One Year Ago EPS: N/A

Indaptus Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Indaptus Therapeutics Announcement Details

• Date: 3/13/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Indaptus Therapeutics (NASDAQ:INDP), is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors. The company is also exploring applications in antiviral immunotherapies, reflecting the versatility of its platform. By combining advanced engineering techniques with scalable manufacturing processes, Indaptus aims to deliver off-the-shelf therapies to patients with unmet medical needs.

Headquartered in the United States, Indaptus collaborates with academic institutions and contract research organizations to advance discovery and clinical translation. Since its inception, the company has established state-of-the-art research and development facilities to support process development, preclinical evaluation, and future clinical manufacturing. Led by a management team with deep experience in cell and gene therapy development, Indaptus is positioned to move its lead programs into early-phase clinical trials and expand its strategic partnerships in the biopharmaceutical industry.